14,575 results match your criteria Annals of the Rheumatic Diseases[Journal]


Epidemiology and socioeconomic impact of the rheumatic diseases on indigenous people: an invisible syndemic public health problem.

Ann Rheum Dis 2018 Jul 14. Epub 2018 Jul 14.

Rheumatology Department, Regional Center for Autoimmune and Rheumatic Diseases (Centro Regional de Enfermedades Autoinmunes y Reumaticas, CREAR), Rosario, Santa Fe, Argentina.

Epidemiological studies in Latin America suggest indigenous people lack proper healthcare for musculoskeletal (MSK) and rheumatic diseases.

Objectives: This study aimed to estimate the prevalence of MSK disorders and rheumatic diseases in eight Latin American indigenous communities, and to identify which factors influence such prevalence using network analysis and syndemic approach.

Methods: This is a cross-sectional, community-based census study according to Community-Oriented Program for the Control of Rheumatic Diseases methodology. Read More

View Article

Use of dual-energy CT to detect and depict bone marrow oedema in rheumatoid arthritis: is it ready to substitute MRI?

Ann Rheum Dis 2018 Jul 12. Epub 2018 Jul 12.

Department of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.

View Article

Apolipoprotein B binds to enolase-1 and aggravates inflammation in rheumatoid arthritis.

Ann Rheum Dis 2018 Jul 11. Epub 2018 Jul 11.

Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Medical Research Center, Seoul National University, Seoul, South Korea.

Objective: Immune cells from patients with rheumatoid arthritis (RA) express more enolase-1 (ENO1) on their surface than those from healthy subjects, and they elicit an enhanced inflammatory response. This study is aimed to identify the ligands of ENO1 that could promote inflammatory loops in vitro and enhance the arthritis severity in vivo.

Methods: ENO1-binding proteins in RA synovial fluid were identified by mass spectromety, and affinity to ENO1 was evaluated by means of a ligand blotting and binding assay, surface plasmon resonance and confocal microscopy. Read More

View Article
July 2018
3 Reads

2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis.

Ann Rheum Dis 2018 Jul 11. Epub 2018 Jul 11.

Department of Orthopaedics, Rehabilitation and Physical Therapy, Leiden University Medical Center, Leiden, Netherlands.

Regular physical activity (PA) is increasingly promoted for people with rheumatic and musculoskeletal diseases as well as the general population. We evaluated if the public health recommendations for PA are applicable for people with inflammatory arthritis (iA; Rheumatoid Arthritis and Spondyloarthritis) and osteoarthritis (hip/knee OA) in order to develop evidence-based recommendations for advice and guidance on PA in clinical practice. The EULAR standardised operating procedures for the development of recommendations were followed. Read More

View Article
July 2018
2 Reads

Glucocorticoid receptor in stromal cells is essential for glucocorticoid-mediated suppression of inflammation in arthritis.

Ann Rheum Dis 2018 Jul 11. Epub 2018 Jul 11.

Institute for Comparative Molecular Endocrinology, University of Ulm, Ulm, Germany.

Background: Glucocorticoid (GC) therapy is frequently used to treat rheumatoid arthritis due to potent anti-inflammatory actions of GCs. Direct actions of GCs on immune cells were suggested to suppress inflammation.

Objectives: Define the role of the glucocorticoid receptor (GR) in stromal cells for suppression of inflammatory arthritis. Read More

View Article
July 2018
1 Read

Characterisation of the nasal microbiota in granulomatosis with polyangiitis.

Ann Rheum Dis 2018 Jul 11. Epub 2018 Jul 11.

Division of Rheumatology and the Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Objectives: Prior studies have suggested a potential link between nasal microbes and granulomatosis with polyangiitis (GPA; Wegener's), but these studies relied on culture-dependent methods. This study comprehensively examined the entire community of nasal microbiota (bacteria and fungi) in participants with GPA compared with healthy controls using deep sequencing methods.

Methods: 16S rRNA and internal transcribed spacer gene sequencing were performed on nasal microbial DNA isolated from nasal swabs of 60 participants with GPA and 41 healthy controls. Read More

View Article
July 2018
1 Read

Synovial macrophage M1 polarisation exacerbates experimental osteoarthritis partially through R-spondin-2.

Ann Rheum Dis 2018 Jul 10. Epub 2018 Jul 10.

Department of Orthopedics, Academy of Orthopedics - Guangdong Province, Orthopedic Hospital of Guangdong Province, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.

Objectives: To investigate the roles and regulatory mechanisms of synovial macrophages and their polarisation in the development of osteoarthritis (OA).

Methods: Synovial tissues from normal patients and patients with OA were collected. M1 or M2-polarised macrophages in synovial tissues of patients with OA and OA mice were analysed by immunofluorescence and immunohistochemical staining. Read More

View Article

Tetraspanin CD82 affects migration, attachment and invasion of rheumatoid arthritis synovial fibroblasts.

Ann Rheum Dis 2018 Jul 6. Epub 2018 Jul 6.

Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig University Giessen, Bad Nauheim, Germany.

Tetraspanins function as membrane adaptors altering cell-cell fusion, antigen presentation, receptor-mediated signal transduction and cell motility via interaction with membrane proteins including other tetraspanins and adhesion molecules such as integrins. CD82 is expressed in several malignant cells and well described as tumour metastasis suppressor. Rheumatoid arthritis (RA) is based on persistent synovial inflammation and joint destruction driven to a large extent by transformed-appearing activated synovial fibroblasts (SF) with an increased migratory potential. Read More

View Article

Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry.

Ann Rheum Dis 2018 Jul 6. Epub 2018 Jul 6.

Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.

Objective: To establish in a global setting the relationships between countries' socioeconomic status (SES), measured biological disease modifying antirheumatic drug (bDMARD)-usage and disease outcomes. To assess if prescription and reimbursement rules and generic access to medication relates to a countries' bDMARD-usage.

Methods: Data on disease activity and drug use from countries that had contributed at least 100 patients were extracted from the METEOR database. Read More

View Article

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Ann Rheum Dis 2018 Jul 6. Epub 2018 Jul 6.

Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.

Objectives: Biologic disease-modifying antirheumatic drugs (bDMARDs) have revolutionised treatment and outcomes for rheumatoid arthritis (RA). The expanding repertoire allows the option of switching bDMARD if current treatment is not effective. For some patients, even after switching, disease control remains elusive. Read More

View Article

Overdiagnosis and overtreatment in rheumatology: a little caution is in order.

Ann Rheum Dis 2018 Jul 4. Epub 2018 Jul 4.

Rheumatology & clinical immunology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands.

Overdiagnosis is a term coined by experts in cancer screening to point to indolent cancers detected by screening that would have never led to manifest health problems. Overdiagnosis leads to unnecessary medical care (overtreatment), anxiety and cost. In rheumatology overdiagnosis and overtreatment are hardly discussed but likely present. Read More

View Article

Systematic approach demonstrates enrichment of multiple interactions between non- risk variants and risk alleles in rheumatoid arthritis.

Ann Rheum Dis 2018 Jul 2. Epub 2018 Jul 2.

Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Objective: In anti-citrullinated protein antibody positive rheumatoid arthritis (ACPA-positive RA), a particular subset of alleles, called shared epitope (SE) alleles, is a highly influential genetic risk factor. Here, we investigated whether non- single nucleotide polymorphisms (SNP), conferring low disease risk on their own, interact with SE alleles more frequently than expected by chance and if such genetic interactions influence the SE effect concerning risk to ACPA-positive RA.

Methods: We computed the attributable proportion (AP) due to additive interaction at genome-wide level for two independent ACPA-positive RA cohorts: the Swedish epidemiological investigation of rheumatoid arthritis (EIRA) and the North American rheumatoid arthritis consortium (NARAC). Read More

View Article
July 2018
1 Read

Variation in antinuclear antibody detection: need for clear expectations and additional studies.

Ann Rheum Dis 2018 Jun 29. Epub 2018 Jun 29.

Inova Diagnostics Inc., San Diego, California, USA.

View Article
June 2018
2 Reads

Non-classical monocytes as mediators of tissue destruction in arthritis.

Ann Rheum Dis 2018 Jun 29. Epub 2018 Jun 29.

Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

Objectives: Bone destruction in rheumatoid arthritis is mediated by osteoclasts (OC), which are derived from precursor cells of the myeloid lineage. The role of the two monocyte subsets, classical monocytes (expressing CD115, Ly6C and CCR2) and non-classical monocytes (which are CD115 positive, but low in Ly6C and CCR2), in serving as precursors for OC in arthritis is still elusive.

Methods: We investigated CCR2 mice, which lack circulating classical monocytes, crossed into hTNFtg mice for the extent of joint damage. Read More

View Article
June 2018
2 Reads

Can we further SPARkle the SPAR model?

Ann Rheum Dis 2018 Jun 29. Epub 2018 Jun 29.

Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India.

View Article

Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.

Ann Rheum Dis 2018 Jun 27. Epub 2018 Jun 27.

Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK.

Objective: We aimed to assess risk factors for the development of severe infection in patients with antineutrophil cytoplasm antibody-associated vasculitis (AAV) receiving rituximab.

Methods: 192 patients with AAV were identified. Univariate and multivariate analyses were performed to identify risk factors for severe infection following rituximab. Read More

View Article
June 2018
2 Reads

Checkpoint inhibitors and arthritis: seeking balance between victories and defeats.

Ann Rheum Dis 2018 Jun 27. Epub 2018 Jun 27.

Clínica Médica, Hospital Santo Antonio, Salvador, Bahia, Brazil.

View Article

Response to: 'Infrapatellar fat pad resection during total knee replacement: yet another reason?' by Ryan.

Ann Rheum Dis 2018 Jun 27. Epub 2018 Jun 27.

Clinical Research Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

View Article

Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies.

Ann Rheum Dis 2018 Jun 26. Epub 2018 Jun 26.

Sanquin Research and Landsteiner Laboratory, Department of Immunopathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Objectives: Therapeutic antibodies can provoke an antidrug antibody (ADA) response, which can form soluble immune complexes with the drug in potentially high amounts. Nevertheless, ADA-associated adverse events are usually rare, although with notable exceptions including infliximab. The immune activating effects and the eventual fate of these 'anti-idiotype' complexes are poorly studied, hampering assessment of ADA-associated risk of adverse events. Read More

View Article
June 2018
3 Reads

Response to: 'Protective effects of antimalarials in Chinese patients with systemic lupus erythematosus' by Wang .

Ann Rheum Dis 2018 Jun 26. Epub 2018 Jun 26.

Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Mainz, Mainz, Germany.

View Article
June 2018
1 Read

Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus.

Ann Rheum Dis 2018 Jun 26. Epub 2018 Jun 26.

Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.

Objective: Despite the importance of type I interferon (IFN-I) in systemic lupus erythematosus (SLE) pathogenesis, the mechanisms of IFN-I production have not been fully elucidated. Recognition of nucleic acids by DNA sensors induces IFN-I and interferon-stimulated genes (ISGs), but the involvement of cyclic guanosine monophosphate (GMP)-AMP synthase (cGAS) and stimulator of interferon genes (STING) in SLE remains unclear. We studied the role of the cGAS-STING pathway in the IFN-I-producing cascade driven by SLE serum. Read More

View Article

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.

Ann Rheum Dis 2018 Jun 26. Epub 2018 Jun 26.

Department of Translational Development, Celgene Corporation, Summit, New Jersey, USA.

Objectives: and encoding transcription factors Ikaros and Aiolos) are susceptibility loci for systemic lupus erythematosus (SLE). The pharmacology of iberdomide (CC-220), a cereblon () modulator targeting Ikaros and Aiolos, was studied in SLE patient cells and in a phase 1 healthy volunteer study.

Methods: , and gene expression was measured in peripheral blood mononuclear cells (PBMC) from patients with SLE and healthy volunteers. Read More

View Article
June 2018
4 Reads

Protective effects of antimalarials in Chinese patients with systemic lupus erythematosus.

Ann Rheum Dis 2018 Jun 26. Epub 2018 Jun 26.

Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.

View Article
June 2018
2 Reads

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Ann Rheum Dis 2018 Jun 26. Epub 2018 Jun 26.

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

Objectives: To evaluate the efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS).

Methods: A total of 159 patients with biological-naïve AS, with active disease (Bath Ankylosing Spondylitis Disease Activity Index score of ≥4), were randomised (1:1:1:1) to risankizumab (18 mg single dose, 90 mg or 180 mg at day 1 and weeks 8, 16 and 24) or placebo over a 24-week blinded period. The primary outcome was a 40% improvement in Assessment in Spondylo Arthritis International Society (ASAS40) at week 12. Read More

View Article
June 2018
3 Reads

Methotrexate and BAFF interaction prevents immunization against TNF inhibitors.

Ann Rheum Dis 2018 Jun 23. Epub 2018 Jun 23.

Rheumatology Department, Université Paris-Sud-CEA-INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, Hôpitaux Universitaires Paris-Sud-Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre, France.

Objectives: TNF inhibitors (TNFi) can induce anti-drug antibodies (ADA) in patients with autoimmune diseases (AID) leading to clinical resistance. We explored a new way of using methotrexate (MTX) to decrease this risk of immunisation.

Methods: We treated BAFF transgenic (BAFFtg) mice, a model of AID in which immunisation against biologic drugs is high, with different TNFi. Read More

View Article
June 2018
23 Reads

Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes.

Ann Rheum Dis 2018 Jun 22. Epub 2018 Jun 22.

Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.

Objective: To explore associations between remission, based on clinical and ultrasound definitions, and future good radiographic and physical outcome in early rheumatoid arthritis (RA).

Methods: Newly diagnosed patients with RA followed a treat-to-target strategy incorporating ultrasound information in the Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen (ARCTIC) trial. We defined 6-month remission according to Disease Activity Score, Disease Activity Score in 28 joints-erythrocyte sedimentation rate, American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean criteria, Simplified Disease Activity Index, Clinical Disease Activity Index and two ultrasound definitions (no power Doppler signal, grey scale score ≤2). Read More

View Article

Response to: 'Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1' by Michot .

Ann Rheum Dis 2018 Jun 22. Epub 2018 Jun 22.

Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France.

View Article

Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status.

Ann Rheum Dis 2018 Jun 21. Epub 2018 Jun 21.

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK.

Objective: To evaluate clinical, interferon and imaging predictors of progression from 'At Risk' to autoimmune connective tissue diseases (AI-CTDs).

Methods: A prospective observational study was conducted in At-Risk of AI-CTD (defined as antinuclear antibody (ANA) positive; ≤1 clinical systemic lupus erythematosus (SLE) criterion; symptom duration <12 months and treatment-naïve). Bloods and skin biopsy (non-lesional) were analysed for two interferon-stimulated gene expression scores previously described (IFN-Score-A and IFN-Score-B). Read More

View Article
June 2018
1 Read

Response to: 'Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor' by Chan and Bass.

Ann Rheum Dis 2018 Jun 20. Epub 2018 Jun 20.

Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.

View Article

TLR4CXCR4 plasma cells drive nephritis development in systemic lupus erythematosus.

Ann Rheum Dis 2018 Jun 20. Epub 2018 Jun 20.

Department of Pathology and Shenzhen Institute of Research and Innovation, The University of Hong Kong, Hong Kong, China.

Objectives: In patients with systemic lupus erythematosus (SLE), immune tolerance breakdown leads to autoantibody production and immune-complex glomerulonephritis. This study aimed to identify pathogenic plasma cells (PC) in the development of lupus nephritis.

Methods: PC subsets in peripheral blood and renal tissue of patients with SLE and lupus mice were examined by flow cytometry and confocal microscopy, respectively. Read More

View Article
June 2018
2 Reads

Treatment of hip osteoarthritis with glucocorticoids.

Ann Rheum Dis 2018 Jun 20. Epub 2018 Jun 20.

Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.

View Article
June 2018
1 Read

Connective tissue growth factor contributes to joint homeostasis and osteoarthritis severity by controlling the matrix sequestration and activation of latent TGFβ.

Ann Rheum Dis 2018 Jun 20. Epub 2018 Jun 20.

Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.

Objectives: One mechanism by which cartilage responds to mechanical load is by releasing heparin-bound growth factors from the pericellular matrix (PCM). By proteomic analysis of the PCM, we identified connective tissue growth factor (CTGF) and here investigate its function and mechanism of action.

Methods: Recombinant CTGF (rCTGF) was used to stimulate human chondrocytes for microarray analysis. Read More

View Article

Time to change the primary outcome of lupus trials.

Ann Rheum Dis 2018 Jun 19. Epub 2018 Jun 19.

Pôle de Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.

View Article

Rituximab in ANCA-associated vasculitis: fewer infusions or ultra low-dose maintenance therapy?

Ann Rheum Dis 2018 Jun 19. Epub 2018 Jun 19.

Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation.

View Article
June 2018
1 Read

Inconsistency between supplement and article?

Authors:
Hakan Babaoglu

Ann Rheum Dis 2018 Jun 19. Epub 2018 Jun 19.

Department of Internal Medicine, Division of Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey.

View Article

Quantitative imaging of inflammatory disease: are we missing a trick?

Ann Rheum Dis 2018 Jun 16. Epub 2018 Jun 16.

Department of Medical Physics, University College Hospitals Trust, London, UK.

View Article

Response to: 'Association between use of non-steroidal anti-inflammatory drugs and risk of myocardial infarction in patients with spondyloarthritis and osteoarthritis'.

Ann Rheum Dis 2018 Jun 16. Epub 2018 Jun 16.

Department of Medicine, Clin Epi Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts, USA.

View Article

Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis.

Ann Rheum Dis 2018 Jun 12. Epub 2018 Jun 12.

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Introduction: Individual patients with rheumatoid arthritis (RA) show divergent specific anti-citrullinated protein/peptide antibodies (ACPA) patterns, but hitherto no individual ACPA specificity has consistently been linked to RA pathogenesis. ACPA are also implicated in immune complexes (IC)-associated joint pathology, but until now, there has been no method to investigate the role of individual ACPA in RA IC formation and IC-associated pathogenesis.

Methods: We have developed a new technique based on IC binding to C1q-coated magnetic beads to purify and solubilise circulating IC in sera and synovial fluids (SF) from 77 patients with RA. Read More

View Article
June 2018
1 Read

The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: the STARTER study.

Ann Rheum Dis 2018 Jun 9. Epub 2018 Jun 9.

Dipartimento di Scienze Cliniche e Biologiche, Universita` degli Studi di Torino, Turin, Italy.

Objective: To define the role of ultrasound (US) for the assessment of patients with rheumatoid arthritis (RA) in clinical remission, including joint and tendon evaluation.

Methods: A multicentre longitudinal study has been promoted by the US Study Group of the Italian Society for Rheumatology. 25 Italian centres participated, enrolling consecutive patients with RA in clinical remission. Read More

View Article
June 2018
2 Reads

Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis.

Ann Rheum Dis 2018 Aug 8;77(8):1099-1106. Epub 2018 Jun 8.

Rheumatology, UPMC, Institut Pierre Louis d'épidémiologie et Santé publique, GRC 08, Paris, France.

Background: Recent advances in knowledge of the pathogenesis of rheumatoid arthritis (RA) has led to promoting very early intervention.

Objectives: To assess the efficacy of therapeutic interventions in preventing or delaying RA onset with a systematic literature review (SLR) and meta-analysis (MA).

Methods: The SLR aimed to include all reports of randomised controlled trials of disease-modifying antirheumatic drugs or glucocorticoids used in patients presenting genetic and/or environmental risk factors for RA and/or systemic autoimmunity associated with RA, and/or symptoms without clinical arthritis and/or unclassified arthritis and in patients with RA. Read More

View Article
August 2018
6 Reads

Response to: 'Serum complement factor C5a in IgG4-related disease' by Fukui .

Ann Rheum Dis 2018 Jun 6. Epub 2018 Jun 6.

Division of Rheumatology, Department of Internal Medicine, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan.

View Article
June 2018
1 Read

Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.

Ann Rheum Dis 2018 Jun 6. Epub 2018 Jun 6.

Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.

Objectives: To identify the predictive clinical characteristics and establish a prediction model for the progression of mild interstitial lung disease (ILD) in patients with systemic sclerosis (SSc).

Methods: Patients with SSc from two independent prospective cohorts were included in this observational study. All patients fulfilled the 2013 American College of Rheumatology/European League Against Rheumatism criteria, had mild ILD at baseline diagnosed by High-Resolution Computed Tomography (HRCT), available baseline and ≥1 annual follow-up pulmonary function tests and no concomitant pulmonary hypertension or airflow obstruction. Read More

View Article
June 2018
5 Reads

Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls.

Ann Rheum Dis 2018 Jun 6. Epub 2018 Jun 6.

Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.

Objectives: To compare (1) Short Form-36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS), scale scores and Short Form-6 dimensions (SF-6D) between patients with rheumatoid arthritis (RA) and patients with psoriatic arthritis (PsA) and Norwegian general population controls and (2) improvements in these measures between patients with RA and PsA.

Methods: Analyses of covariance were performed to compare SF-36 measures between first-time enrolled patients with RA (n=3898) and PsA (n=1515) from the prospective observational multicentre NORwegian-Disease Modifying Anti-Rheumatic Drug study (6 months follow-up) and general population controls (n=2323).

Results: In age and gender-adjusted analyses, patients with PsA compared with patients with RA had similar PCS, MCS and SF-6D (p≥0. Read More

View Article
June 2018
3 Reads

Serum complement factor C5a in IgG-related disease.

Ann Rheum Dis 2018 Jun 6. Epub 2018 Jun 6.

Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

View Article
June 2018
1 Read